Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 597Lung Neoplasms 187Neoplasms 66Neoplasm Metastasis 46Mesothelioma, Malignant 45Adenocarcinoma of Lung 42Mesothelioma 39Colorectal Neoplasms 29Carcinoma 23Breast Neoplasms 23Parkinson Disease 4, Autosomal Dominant Lewy Body 21Meningeal Carcinomatosis 19Head and Neck Neoplasms 19Brain Neoplasms 18Ovarian Neoplasms 17Adenocarcinoma 15Small Cell Lung Carcinoma 14NSCLC 14Pancreatic Neoplasms 12Melanoma 12Squamous Cell Carcinoma of Head and Neck 11Recurrence 11Lung Diseases 10Carcinoma, Transitional Cell 10Uterine Cervical Neoplasms 9Neoplasms by Site 9Adenocarcinoma, Bronchiolo-Alveolar 9Thoracic Neoplasms 8Non-squamous Non-small Cell Lung Cancer 8Carcinoma, Bronchogenic 8

Interventions

pembrolizumab 1patritumab deruxtecan 1Platinum Compounds 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Nonsquamous Non-small Cell Lung Cancer × Pemetrexed × Clear all
NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Taizhou Hanzhong biomedical co. LTD

Phase 2/3 Unknown
700 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡